Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of CA$26.78K rose 7.2% year over year, ahead of the -69.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of -69.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the cash flow
- Latest · FY2025
- 101.98K CAD
- Year-over-year change
- -72.7%
- 4-year CAGR
- -17.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 101.98K | -72.7% |
| FY2024 | 2024-12-31 | 373.11K | +50.2% |
| FY2023 | 2023-12-31 | 248.36K | +12.9% |
| FY2022 | 2022-12-31 | 219.91K | -0.2% |
| FY2021 | 2021-12-31 | 220.42K | — |
Depreciation & Amortization vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -69.2% is the lowest of 9, against a peer median of +9.4%.
- Over three fiscal years its annual growth of -22.6% compares with a peer median of -7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.58M USD | -9.6% | -3.5% | 26.0% | |
| LTM Jun 2025 | ₪8.45M ILS | +33.4% | +13.6% | 3.5% | |
| LTM Mar 2026 | $1.38M USD | +41.1% | +2.4% | 9.0% | |
| FY2025 | $704K USD | +6.7% | -11.4% | 1100.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $616K USD | +72.1% | -24.1% | — |
| LTM Mar 2026 | $452K USD | +12.2% | +3.6% | — | |
| LTM Mar 2026 | €377.74K EUR | -20.5% | -12.3% | 1287.9% | |
| LTM Mar 2026 | CA$103.77K CAD | -69.2% | -22.6% | — | |
| LTM Mar 2026 | $44K USD | -43.6% | -22.8% | 41.9% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K USD | — | — | — |
| Peer median (excluding CRDL) | — | +9.4% | -7.5% | 34.0% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | (9.16M) | 0 | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.16M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | (545.88K) | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 200.33K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | 0 | 0 | 0 |
| Other Working Capital | (2.27M) | 5.89M | (746.2K) | (849.82K) | (868.76K) |
| Other Non-Cash Items | 4.21M | 1.89M | (911.39K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18M) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.41M | (0) | 0 | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24M) | (25.08M) | (23.88M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.